Overview
The marketing authorisation for Pandemic Influenza Vaccine H5N1 Baxter has been withdrawn at the request of the marketing-authorisation holder.
Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Summary for the public
English (EN) (190.78 KB - PDF)
български (BG) (302.71 KB - PDF)
español (ES) (196.16 KB - PDF)
čeština (CS) (251.73 KB - PDF)
dansk (DA) (193.38 KB - PDF)
Deutsch (DE) (215.06 KB - PDF)
eesti keel (ET) (186.14 KB - PDF)
ελληνικά (EL) (312.29 KB - PDF)
français (FR) (203.06 KB - PDF)
hrvatski (HR) (237.92 KB - PDF)
italiano (IT) (196.36 KB - PDF)
latviešu valoda (LV) (250.74 KB - PDF)
lietuvių kalba (LT) (271.9 KB - PDF)
magyar (HU) (240.63 KB - PDF)
Malti (MT) (261.83 KB - PDF)
Nederlands (NL) (203.3 KB - PDF)
polski (PL) (254.04 KB - PDF)
português (PT) (198.47 KB - PDF)
română (RO) (256.87 KB - PDF)
slovenčina (SK) (252.83 KB - PDF)
slovenščina (SL) (229.82 KB - PDF)
Suomi (FI) (189.11 KB - PDF)
svenska (SV) (216.89 KB - PDF)
Product information
Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Product Information
English (EN) (2.32 MB - PDF)
български (BG) (2.86 MB - PDF)
español (ES) (2.31 MB - PDF)
čeština (CS) (2.67 MB - PDF)
dansk (DA) (2.3 MB - PDF)
Deutsch (DE) (2.48 MB - PDF)
eesti keel (ET) (2.2 MB - PDF)
ελληνικά (EL) (2.88 MB - PDF)
français (FR) (2.43 MB - PDF)
hrvatski (HR) (2.52 MB - PDF)
íslenska (IS) (2.32 MB - PDF)
italiano (IT) (2.36 MB - PDF)
latviešu valoda (LV) (2.55 MB - PDF)
lietuvių kalba (LT) (2.63 MB - PDF)
magyar (HU) (2.53 MB - PDF)
Malti (MT) (2.75 MB - PDF)
Nederlands (NL) (2.32 MB - PDF)
norsk (NO) (2.22 MB - PDF)
polski (PL) (2.78 MB - PDF)
português (PT) (2.27 MB - PDF)
română (RO) (2.66 MB - PDF)
slovenčina (SK) (2.76 MB - PDF)
slovenščina (SL) (2.46 MB - PDF)
Suomi (FI) (2.26 MB - PDF)
svenska (SV) (2.23 MB - PDF)
Latest procedure affecting product information: IAIN/0032
01/02/2023
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Pandemic Influenza Vaccine H5N1 Baxter : EPAR - All Authorised presentations
English (EN) (36.17 KB - PDF)
български (BG) (77.58 KB - PDF)
español (ES) (36.39 KB - PDF)
čeština (CS) (68.82 KB - PDF)
dansk (DA) (37.85 KB - PDF)
Deutsch (DE) (36.96 KB - PDF)
eesti keel (ET) (38.06 KB - PDF)
ελληνικά (EL) (75.53 KB - PDF)
français (FR) (36.19 KB - PDF)
hrvatski (HR) (117.77 KB - PDF)
íslenska (IS) (36.21 KB - PDF)
italiano (IT) (35.28 KB - PDF)
latviešu valoda (LV) (69.81 KB - PDF)
lietuvių kalba (LT) (68.26 KB - PDF)
magyar (HU) (69.83 KB - PDF)
Malti (MT) (70.99 KB - PDF)
Nederlands (NL) (37.07 KB - PDF)
norsk (NO) (37.36 KB - PDF)
polski (PL) (70.96 KB - PDF)
português (PT) (37.4 KB - PDF)
română (RO) (68.56 KB - PDF)
slovenčina (SK) (70.07 KB - PDF)
slovenščina (SL) (53.33 KB - PDF)
Suomi (FI) (36.84 KB - PDF)
svenska (SV) (36.12 KB - PDF)
Product details
- Name of medicine
- Pandemic Influenza Vaccine H5N1 Baxter AG
- Active substance
- influenza vaccine (whole virion, inactivated) containing antigen of: A/Vietnam/1203/2004 (H5N1)
- International non-proprietary name (INN) or common name
- pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture)
- Therapeutic area (MeSH)
- Influenza, Human
- Immunization
- Disease Outbreaks
- Anatomical therapeutic chemical (ATC) code
- J07BB01
Pharmacotherapeutic group
VaccinesTherapeutic indication
Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.
Authorisation details
- EMA product number
- EMEA/H/C/001200
Exceptional circumstances
This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance.
- Marketing authorisation holder
- Resilience Biomanufacturing Ireland Limited
Resilience Biomanufacturing Ireland Limited
Shelbourne Buildings 2
Cramptom Avenue
Dublin 4
D04 W3V6
IRELAND - Marketing authorisation issued
- 16/10/2009
- Revision
- 8
Assessment history
Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (829.88 KB - PDF)
Pandemic Influenza Vaccine H5N1-H-C-1200-P46-0020 : EPAR - Assessment Report
English (EN) (1.24 MB - PDF)
Pandemic Influenza Vaccine H5N1 Baxter-H-C-1200-II-0015 : EPAR - Assessment Report - Variation
English (EN) (1.91 MB - PDF)
Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Paediatric investigation plan compliance statement
English (EN) (113.32 KB - PDF)
CHMP post-authorisation summary of positive opinion for Pandemic influenza vaccine H5N1 Baxter
English (EN) (104.85 KB - PDF)
Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Public assessment report
English (EN) (114.87 KB - PDF)
Committee for medicinal products for human use, summary of positive opinion for Pandemic Influenza Vaccine H5N1 Baxter
English (EN) (62.79 KB - PDF)
News on Pandemic Influenza Vaccine H5N1 Baxter AG
More information on Pandemic Influenza Vaccine H5N1 Baxter
Public statement on Pandemic Influenza Vaccine H5N1 Baxter : Withdrawal of the marketing authorisation in the European Union
English (EN) (91.97 KB - PDF)